fdmt: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by financing activities	978	862
Net decrease in cash and cash equivalents	-100,781	-72,177
Cash and cash equivalents at beginning of period	149,336	-
Cash and cash equivalents at end of period	48,555	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by financing activities	978	862
Net decrease in cash and cash equivalents	-100,781	-72,177
Cash and cash equivalents at beginning of period	149,336	-
Cash and cash equivalents at end of period	48,555	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

4D Molecular Therapeutics, Inc. (FDMT)